Combinatorial in vivo genome editing identifies widespread epistasis during lung tumorigenesis
Jess D. HebertiD, Yuning J. TangiD, Márton SzamecziD, Laura AndrejkaiD, Steven S. LopeziD, Dmitri A. PetroviD, Gábor Zoltán BorossiD, Monte M. WinslowiD
Abstract
Lung adenocarcinoma, the most common subtype of lung cancer, is genomically complex, with tumors containing tens to hundreds of non-synonymous mutations. However, little is understood about how genes interact with each other to enable tumorigenesis in vivo, largely due to a lack of methods for investigating genetic interactions in a high-throughput and multiplexed manner. Here, we employed a novel platform to generate tumors with all pairwise inactivation of ten tumor suppressor genes within an autochthonous mouse model of oncogenic KRAS-driven lung cancer. By quantifying the fitness of tumors with every single and double mutant genotype, we show that most tumor suppressor genetic interactions exhibited negative epistasis, with diminishing returns on tumor fitness. In contrast, Apc inactivation showed positive epistasis with the inactivation of several other genes, including dramatically synergistic effects on tumor fitness in combination with Lkb1 or Nf1 inactivation. This approach has the potential to expand the scope of genetic interactions that may be functionally characterized in vivo, which could lead to a better understanding of how complex tumor genotypes impact each step of carcinogenesis.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 1.18
- Field percentile
- top 26%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma
M. Yousefi, L. Andrejka, … G. Boross·bioRxiv·Jan 30, 2023
- Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
G. Foggetti, C. Li, … K. Politi·Cancer DiscoveryPeer-reviewed·Mar 11, 2021
- Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
Collin M. Blakely, Thomas B.K. Watkins, … Trever G. Bivona·bioRxiv·Mar 16, 2017
- Oncogenic context shapes the fitness landscape of tumor suppression
L. M. Blair, J. M. Juan, … I. P. Winters·Nature CommunicationsPeer-reviewed·Oct 12, 2023
- Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth
R. Tang, E. G. Shuldiner, … M. M. Winslow·bioRxiv·Jul 8, 2021
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities
M. Yousefi, G. Boross, … M. M. Winslow·bioRxiv·Oct 20, 2021